adenosine diphosphate has been researched along with lfm a13 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bartell, S; Mahajan, S; Tibbles, HE; Uckun, FM; Vassilev, A; Zheng, Y | 1 |
1 other study(ies) available for adenosine diphosphate and lfm a13
| Article | Year |
|---|---|
The anti-leukemic Bruton's tyrosine kinase inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism.
Topics: Adenosine Diphosphate; Agammaglobulinaemia Tyrosine Kinase; Amides; Animals; Aspirin; Bleeding Time; Catalytic Domain; Collagen; Drug Design; Drug Evaluation, Preclinical; Enzyme Inhibitors; Fibrinolytic Agents; Humans; Janus Kinase 3; Male; Mice; Mice, Inbred ICR; Nitriles; Peptide Fragments; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Protein-Tyrosine Kinases; Pulmonary Embolism; Quinazolines; Receptors, Collagen; Signal Transduction; Thrombin; Thromboembolism; Thromboplastin | 2003 |